2. UroToday Home
  3. Video Lectures

mCRPC Treatment Videos

First Patient Experience with Pre-Chemotherapy Pluvicto™ for mCRPC Treatment - James Wasielewski
April 17, 2025
Details
First Patient Treated with Pluvicto™ in Pre-Chemotherapy Setting Following FDA Approval - Steven Finkelstein
April 4, 2025
Details
Prognostic Value of ctDNA Fraction in Metastatic Castration-Resistant Prostate Cancer - Alessio Crippa
March 29, 2025
Details
FDA Approval of 177Lu-PSMA-617 for Taxane-Naive mCRPC - Oliver Sartor
March 28, 2025
Details
PARASEC Study Reveals Real-World Treatment Patterns After Darolutamide in ARAMIS Trial - Javier Puente
March 27, 2025
Details
Cognitive Effects of Abiraterone vs Enzalutamide in Metastatic Castration-Resistant Prostate Cancer - Alicia Morgans
March 25, 2025
Details
PREDICT Trial Investigates Biomarker-Guided Treatment for Advanced Prostate Cancer - Rana McKay
March 25, 2025
Details
Real-World Treatment Delays Between Lutetium-177 and Cabazitaxel in Advanced Prostate Cancer - Yeonjung Jo & Umang Swami
March 25, 2025
Details
Bone-Protective Agents and Survival Benefits in PEACE-3 Trial Subgroup Analysis - Fred Saad
March 23, 2025
Details
TRITON3 Final Overall Survival Results for Rucaparib in BRCA-Mutated Prostate Cancer - Alan Bryce
March 20, 2025
Details
Talazoparib and Enzalutamide in Unselected mCRPC Patients - Neeraj Agarwal
March 18, 2025
Details
Revisiting HER2 as a Therapeutic Target in Prostate Cancer - Nicole Mavingire
March 18, 2025
Details
Real-World Data on Treatment Patterns After PSMA-Targeted Therapy in mCRPC - Oliver Sartor
March 17, 2025
Details
Targeting Lineage Plasticity in Prostate Cancer with EZH2 Inhibitor Mevrometostat - Michael Schweizer
March 17, 2025
Details
Systematic Review of Real-World Outcomes of Radium-223 in mCRPC Treatment - Rana McKay
March 17, 2025
Details
Phase II ENZA-p Trial Explores Effect of Lutetium PSMA With Enzalutamide - Louise Emmett
March 16, 2025
Details
Cardiovascular Management in Advanced Prostate Cancer - Zeynep Irem Ozay
March 12, 2025
Details
Underutilization of Genomic Testing in Metastatic Castration-Resistant Prostate Cancer - Pedro Barata
March 5, 2025
Details
Lutetium PSMA Therapy in mCRPC: Real-World Evidence from PRECISION Data Platform - Oliver Sartor
March 4, 2025
Details
177-Lutetium-PSMA vs Cabazitaxel: A Real-World mCRPC Study - Mike Wenzel
March 3, 2025
Details
ACCEL Trial Tests Actinium-225-PSMA-62 in Prostate Cancer - Ramy Saleh
February 27, 2025
Details
Real-World Trends in Bone Health Agent Use for Metastatic Prostate Cancer - Umang Swami
February 27, 2025
Details
REDUSE Trial: Comparing Denosumab Dosing Intervals in mCRPC - Arnoud Templeton
February 27, 2025
Details
Talazoparib Improves Survival in HRR-Mutated mCRPC Patients in TALAPRO-2 Trial - Karim Fizazi
February 25, 2025
Details
ASCL1 and FOXA2 in Neuroendocrine Prostate Cancer - Shaghayegh Nouruzi
February 10, 2025
Details
Opevesostat Trial in mCRPC: Targeting Androgen Biosynthesis Upstream for Improved Outcomes - Christian Gratzke
January 27, 2025
Details
ProstACT GLOBAL Trial: Combining PSMA-Targeted Therapy with ARPIs and Docetaxel - Oliver Sartor
January 24, 2025
Details
Combining EZH2 and AR Targeting in Metastatic Castration-Resistant Prostate Cancer - Neeraj Agarwal
January 17, 2025
Details
AR Enhancer Amplification and SSTR1 Downregulation in mCRPC - Xiaolin Zhu
January 16, 2025
Details
Effectiveness of PSMA-Lutetium for Prostate Cancer Liver Metastases - Daniel Childs
January 13, 2025
Details
Tumor Dosimetry in PSMA Therapy: A VISION Substudy Analysis - Ken Herrmann
January 10, 2025
Details
Coagulation Factor X Promotes Resistance to Androgen-Deprivation Therapy in Prostate Cancer - Bianca Calì
January 2, 2025
Details
RaLu Trial: Sequence of Radium Then Lutetium in mCRPC Management - Kambiz Rahbar
December 11, 2024
Details
ctDNA Assay Detects AR Enhancer Alterations Linked to Poor Survival - Russell Pachynski, Aadel Chaudhuri & Christopher Maher
November 18, 2024
Details
Optimal Treatment Sequencing in Metastatic Prostate Cancer "Discussion"
November 15, 2024
Details
Importance of Bone Protection in Prostate Cancer Treatment "Presentation" - Noel Clarke
November 15, 2024
Details
Tailoring PARP Inhibitor Therapy for mCRPC Based on Genetic Alterations "Discussion"
November 15, 2024
Details
Best Use of PARP Inhibitors in mCRPC "Presentation" - Joaquin Mateo
November 15, 2024
Details
PARP Inhibition Dissected – in Which DNA Repair Gene Alterations Works Which PARP Inhibitor? "Presentation" - Johann De Bono
November 15, 2024
Details
How to Manage Side Effects of PARPi? "Presentation" - Elena Castro
November 15, 2024
Details
Combining Lutetium-PSMA with Hormonal Therapy Enhances Prostate Cancer Treatment - Louise Emmett
November 8, 2024
Details
Elevated CBP/p300 Expression Linked to Poor Outcomes in Advanced Prostate Cancer - Ayesha Shafi
November 7, 2024
Details
Highlights in Prostate Cancer Treatment Advances from ESMO 2024 - Ursula Vogl
November 5, 2024
Details
Radium-223 Plus Enzalutamide Improves Survival in mCRPC: PEACE-3 Trial Results, Journal Club - Rashid Sayyid & Zachary Klaassen
November 3, 2024
Details
Epigenetic Profiling Identifies Biomarkers Predicting Resistance to AR-Targeted Therapy in mCRPC - Wilbert Zwart
November 2, 2024
Details
ARROW Study Reveals Iodine-131 PSMA Efficacy in Advanced Cancer - Evan Yu
October 30, 2024
Details
AR Pathway Inhibitors vs Taxanes in mCRPC ProBio Trial - Bram De Laere
October 14, 2024
Details
First-Line Combination Treatment with PARP and Androgen Receptor-Signaling Inhibitors in HRR-Deficient mCRPC: Applying Clinical Study Findings to Clinical Practice in the United States - Beyond the Abstract
October 9, 2024
Details
INSPIRE Trial Investigates Immunotherapy for Molecularly Selected Advanced Prostate Cancer - Niven Mehra
October 7, 2024
Details
STEAP1-Targeted T-Cell Engager Demonstrates Efficacy in mCRPC Patients - William Kevin Kelly
October 3, 2024
Details
Emerging DLL3-Targeted Therapies Demonstrate Efficacy in Neuroendocrine Prostate Cancer - Himisha Beltran
October 3, 2024
Details
Novel Epigenomic Liquid Biopsy Detects PSMA Expression in Prostate Cancer - Jacob Berchuck
October 2, 2024
Details
Advancements in Lutetium-PSMA Therapy for Prostate Cancer: Clinical Trials and Future Directions - Ken Herrmann
October 1, 2024
Details
First-in-Class AR Degrader Shows Promise in Castration-Resistant Prostate Cancer - Dana Rathkopf
October 1, 2024
Details
TALAPRO-2 Analysis: Talazoparib Enzalutamide Combo in Pretreated mCRPC - Neeraj Agarwal
September 30, 2024
Details
CONTACT-02 Trial Results: Cabozantinib Plus Atezolizumab for mCRPC - Neeraj Agarwal
September 30, 2024
Details
PEACE 3 Trial Results Show Promise for Radium-223 and Enzalutamide in Asymptomatic mCRPC - Fred Saad
September 28, 2024
Details
RAPSON Trial Explores Radium223 and Docetaxel Sequencing in mCRPC - Vincenza Conteduca
September 26, 2024
Details
PEACE-3 Trial Results: Radium-223 + Enzalutamide in mCRPC - Bertrand Tombal
September 24, 2024
Details
T-Cell Engagers in Prostate Cancer Treatment - Neeraj Agarwal
September 22, 2024
Details
SPLASH Trial Highlights Radiopharmaceutical Lutetium-177’s Role in Advanced Prostate Cancer Treatment - Oliver Sartor
September 15, 2024
Details
STORM Trial Examines Elective Nodal Radiotherapy in Treating Prostate Cancer Recurrence - Piet Ost
August 24, 2024
Details
Overcoming Hormone Resistance: ARV-766 in Advanced Prostate Cancer - Daniel Petrylak
August 6, 2024
Details
Antibody Drug Conjugate FOR46: Targeting CD46 in mCRPC in Phase 1b Trial - Nonna Shakhnazaryan
August 5, 2024
Details
PSMA PET in Prostate Cancer: Balancing Sensitivity and Clinical Relevance - Ravi Madan
August 1, 2024
Details
Extracellular Vesicles in Prostate Cancer: Multi-Omic Liquid Biopsy - Irene Casanova-Salas & Joaquin Mateo
July 29, 2024
Details
2024 NCCN Guidelines: Managing Bone Health in Prostate Cancer Patients - Rashid Sayyid & Zachary Klaassen
July 26, 2024
Details
2024 NCCN Guidelines: Preventing Skeletal Events in Prostate Cancer - Rashid Sayyid & Zachary Klaassen
July 25, 2024
Details
Cell Surface Targets in mCRPC: Expression Landscape and Therapeutic Potential - Michael Haffner
July 22, 2024
Details
2024 NCCN Guidelines Update: Metastatic Castration-Resistant Prostate Cancer Treatment - Rashid Sayyid & Zachary Klaassen
July 10, 2024
Details
PSMAfore Trial: Lutetium PSMA's Impact on mCRPC Quality of Life - Karim Fizazi
July 2, 2024
Details
Meta-Analysis Evaluates Cardiovascular Risks of AR Inhibitors in Prostate Cancer - Omar El-Taji & Ashwin Sachdeva
June 28, 2024
Details
SECuRE Trial: Copper-67 SAR-bisPSMA Therapy for Prostate Cancer - Geoffrey Johnson
June 24, 2024
Details
Genomic Alterations and Lutetium PSMA Response in Prostate Cancer - Alexandra Sokolova
June 22, 2024
Details
CYCLONE 2 Trial Results: Abemaciclib in Metastatic Castration-Resistant Prostate Cancer - Matthew Smith
June 22, 2024
Details
PSCA CAR T-Cell Therapy for Metastatic CRPC: Phase 1 Trial Results - Tanya Dorff
June 21, 2024
Details
Targeting EZH2 in Prostate Cancer: The Role of Mevrometostat in Preventing Neuroendocrine Differentiation - Michael Schweizer
June 18, 2024
Details
Machine Learning Model Predicts Overall Survival in Metastatic Prostate Cancer - Ali Sabbagh
June 17, 2024
Details
ctDNA Fraction Predicts Response to Lutetium PSMA in TheraP Trial for mCRPC - Edmond Kwan
June 17, 2024
Details
Dose-Escalation of Lutetium PSMA: Final Results from a Phase I/II Trial - Scott Tagawa
June 13, 2024
Details
Prognostic Power of Multi-Modal Artificial Intelligence Biomarker in CHAARTED Trial Subset - Mark Markowski
June 12, 2024
Details
OASIS Project Highlights the Survival Benefits of Rapid PSA Decline with Apalutamide in Prostate Cancer - Benjamin Maughan
June 12, 2024
Details
ARV-766: Efficacy and Safety of a Second-Generation AR Degrader in Prostate Cancer - Daniel Petrylak
June 11, 2024
Details
CHAARTED 2 Study Shows PFS Benefit with Cabazitaxel in Metastatic Prostate Cancer in Phase 2 - Christos Kyriakopoulos
June 11, 2024
Details
Integrating Genetic Variants and Clinical Factors for Improved Prostate Cancer Prognostication - Susan Halabi
June 11, 2024
Details
hK2-Targeted Radioligand Shows Promise in Treating Advanced Prostate Cancer: Phase I Findings - Michael Morris
June 11, 2024
Details
Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-Blind, Phase 3 Trial - Fred Saad
June 10, 2024
Details
Optimizing Lutetium-PSMA Dosing in High-Volume Disease and Special Situations - Louise Emmett
May 24, 2024
Details
The Use of PARP Inhibitors in mCRPC with BRCA1/2 Alterations - Joaquin Mateo
May 22, 2024
Details
Reprogramming Tumor-Associated Macrophages with Glutamine Antagonist JHU083 in Prostate Cancer - Jelani Zarif
May 21, 2024
Details
PARP Inhibitor + AR Signaling Inhibitor Combos Improve mCRPC Outcomes in Meta-Analysis - Rashid Sayyid
April 9, 2024
Details
Alpha vs Beta Emitters in Prostate Cancer Radiopharmaceuticals: Energy, Range, and Cytotoxicity - Alan Bryce
March 5, 2024
Details
COMBAT Trial Yields Promising Results for Bipolar Androgen Therapy Plus Nivolumab in Metastatic Castration-Resistant Prostate Cancer - Mark Markowski & Emmanuel Antonarakis
February 27, 2024
Details
BRCAAWAY Trial: Impact of Abiraterone and Olaparib Combination in Prostate Cancer - Maha Hussain
February 22, 2024
Details
CONTACT-02 Phase III Trial Findings on Cabozantinib-Atezolizumab Combination in mCRPC - Neeraj Agarwal
February 21, 2024
Details
BRCAAway Trial: Where Combination Treatment Improve Patient Outcomes in mCRPC - Daniel George
February 6, 2024
Details
ProBio Trial Demonstrates Improved Outcomes Using Biomarker-Guided Therapy Selection for Metastatic Prostate Cancer - Henrik Grönberg
January 4, 2024
Details
Novel Biomarker Analysis Reveals SPOP Gene Mutation Unlocks Sensitivity to PARP Inhibitor Treatment in Metastatic Castration-Resistant Prostate Cancer - Emmanuel Antonarakis & Jacob Orme
December 12, 2023
Details
Dual Action Hormone Therapy Targeting Two Parts of Androgen Receptor Shows Tolerability and Early Efficacy for EPI-7386 (masofaniten) - Andrew Laccetti
December 4, 2023
Details
Novel STEAP1 Targeted BiTE Therapy Demonstrates Early Efficacy in Phase 1 Trial - William Kevin Kelly
November 17, 2023
Details
Medicare Data Compares Enzalutamide and Abiraterone Outcomes in mCRPC Patients - Dan George
November 16, 2023
Details
Sequencing Therapies in Advanced Prostate Cancer Requires Balancing Many Factors - Rana McKay
November 15, 2023
Details
The PSMAfore Trial and its Role in Shaping Future Prostate Cancer Treatments - Oliver Sartor
November 10, 2023
Details
Exploring the Safety and Efficacy of EPI-7386 in Combination with Enzalutamide in mCRPC - Ronald Tutrone
October 21, 2023
Details
A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy - Beyond the Abstract
August 22, 2023
Details
The ECLIPSE Trial: Investigating Lutetium-177 in the Pre-Chemotherapy Space in Advanced Prostate Cancer - Daniel Saltzstein
July 13, 2023
Details
Impact of Previous Local Treatment on First-line Androgen Receptor Axis Targeted Therapy Response in mCRPC: A Secondary Analysis of the COU-AA-302 Trial - Soumyajit Roy
May 12, 2023
Details
Exploring the Clinical Trial Landscape for Metastatic Castration-Resistant Prostate Cancer: Insights on Genetic Testing, Radiopharmaceuticals, and Promising Trials - Elena Castro
April 25, 2023
Details
Breaking Down Barriers: Feasibility of Internet-based Genetic Testing for Men with Metastatic Prostate Cancer, The GENTleMEN Study -Heather Cheng
April 21, 2023
Details
PSMA-Targeted Radioligand Therapy and Liquid Biopsy Characterizing PSMA Expression in Men with Metastatic Castration-Resistant Prostate Cancer - Andrew Armstrong
April 21, 2023
Details
Elucidating Mechanisms of Resistance to ADT/PI3K-AKT Blockade in PTEN-Deficient mCRPC - Akash Patnaik
April 20, 2023
Details
The ECLIPSE Phase III Trial of Lutetium PSMA-I&T Shows Promise in Advanced Prostate Cancer Treatment - Emmanuel Antonarakis
April 12, 2023
Details
BXCL701 Combined with Pembrolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer of Small Cell Neuroendocrine Phenotype - Rahul Aggarwal
March 20, 2023
Details
Exploring the Latest Advances in Advanced Prostate Cancer Treatment - Oliver Sartor
April 11, 2023
Details
Final Overall Survival Results from the PROpel Phase 3 Trial in First-line Therapy for mCRPC - Fred Saad
March 3, 2023
Details
Clinically Relevant Biomarkers in Castration-Resistant Prostate Cancer - Noel Clarke
January 24, 2023
Details
Combination of Niraparib and Abiraterone Acetate Plus Prednisone Radiographic PFS as a First-Line Therapy in Patients with HRR Gene-Mutated mCRPC, MAGNITUDE - Cora Sternberg
January 18, 2023
Details
Heterogeneity in Multifocal Prostate Cancer - Simpa Salami
January 10, 2023
Details
A Urine-Based Multiplexed Assay for the Early Detection of Aggressive Prostate Cancer – Simpa Salami
January 10, 2023
Details
Rucaparib Monotherapy Improves Radiographic Progression-Free Survival in Patients With Metastatic Castration-Resistant Prostate Cancer: TRITON3 Trial - Alan Bryce
December 20, 2022
Details
Radiographic Progression-Free Survival Correlation with Time-to-Event Endpoints in the VISION Trial - Michael Morris
December 20, 2022
Details
Exploring the Molecular Mechanisms of Tumor Progression in Metastatic Prostate Cancer among Men of African Ancestry (MET-PAAM) - Clayton Yates
December 19, 2022
Details
Bipolar Androgen Therapy in the Management of Prostate Cancer - Samuel Denmeade
December 13, 2022
Details
Developing a Blood-Based Biomarker Platform to Predict Treatment Outcomes in Prostate Cancer Patients - Martin Sjöström
December 12, 2022
Details
Biomarker Analysis to Identify Molecular Signatures Predictive of Response in the COMBAT Study - Emmanuel Antonarakis
December 5, 2022
Details
Exploring the New Landscape of mCRPC: PARP Inhibitors, PSMA Radioligand Therapy, and More - Alicia Morgans
November 22, 2022
Details
Exploring the SPLASH Trial: PSMA I&T Lutetium-177 in Pre-Chemo Metastatic CRPC - Oliver Sartor
November 2, 2022
Details
A Urologist's Perspective on PSMA-Radioligand Therapy in the Treatment Setting of mCRPC - Neal Shore
October 17, 2022
Details
ODM-208: A New Hope for Treatment-Resistant Prostate Cancer - Karim Fizazi
October 11, 2022
Details
A Urologist's Perspective on the PROpel Trial, Olaparib and Abiraterone versus Abiraterone Alone, in the First-Line Metastatic Castration-Resistant Prostate Cancer Setting - Neal Shore
October 6, 2022
Details
Optimal Treatment for Poor Prognosis Metastatic Castration-Resistant Prostate Cancer, Cabazitaxel vs Abi/Enza, Journal Club – Christopher Wallis & Zachary Klaassen
October 6, 2022
Details
Debate: PARP Inhibitors for All mCRPC Patients APCCC 2022 Presentation - Noel Clarke
September 15, 2022
Details
Risk-Adapted Treatment Monitoring in mCRPC APCCC 2022 Presentation - Anwar Padhani
September 14, 2022
Details
Is There Still a Role for Radium-223? APCCC 2022 Presentation - Neal Shore
September 14, 2022
Details
How To Read a Genomic Testing Report APCCC 2022 Presentation - Kim Chi
September 1, 2022
Details
Optimal Treatment Sequencing in mCRPC APCCC 2022 Presentation - Maha Hussain
August 29, 2022
Details
Treating Metastatic Castration-Resistant Prostate Cancer Session Discussion APCCC 2022 Presentation - Silke Gillessen
August 25, 2022
Details
Debate: PARP Inhibitors Only in Selected mCRPC Patients APCCC 2022 Presentation - Johann de Bono
August 18, 2022
Details
Optimizing the Use of Radium-223 Through Multidisciplinary Collaboration - Phillip Koo
July 25, 2022
Details
Treatment with Radium-223 and Effects on Bone Health in Patients with mCRPC - Fred Saad
June 22, 2022
Details
The Use of PARP Inhibitors in Castrate-Resistant Prostate Cancer - Elena Castro & Joaquin Mateo
June 19, 2022
Details
Symptomatic and Health Related Quality of Life Benefits With Olaparib in Men With mCRPC Carrying Mutations in the Homologous Recombination Repair Genes, Journal Club - Christopher Wallis & Zachary Klaassen
May 24, 2022
Details
Shared Decision-Making vs. Physician or Patient-Directed Decisions on Patient Quality of Life and Decision Satisfaction in Metastatic Prostate Cancer - Frank Schumacher
April 14, 2022
Details
Significant Improvement With Continuous Enzalutamide in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer – Axel Merseburger
March 25, 2022
Details
The Risk of Prostate Cancer in Men with Inherited Germline TP53 Variants - Kara Maxwell
March 16, 2022
Details
First Results of MAGNITUDE – Niraparib with Abiraterone Acetate and Prednisone a First-Line Therapy in Metastatic Castration-Resistant Prostate Cancer – Kim Chi
February 24, 2022
Details
Risk Stratification in Metastatic Prostate Cancer: The Genomic Approach - Leanne Schimke
January 11, 2022
Details
Bispecific T-cell Engager (BiTE®) in Development for Treatment of Advanced Prostate Cancer - Oliver Sartor
December 26, 2021
Details
CheckMate 9KD Trial CohortA2 Evaluating Nivolumab + Rucaparib for Chemotherapy-Naïve mCRPC - Daniel Petrylak
November 7, 2021
Details
Decoding the Impact of CHIP on Prostate Cancer Treatment: Implications for PARP Inhibitor Eligibility - Kendal Jensen
October 11, 2021
Details
COSMIC-021 Study: A Breakthrough in Metastatic CRPC Treatment with Cabozantinib and Atezolizumab - Neeraj Agarwal
October 4, 2021
Details
Health-Related Quality of Life (HRQoL) From the Phase 3 VISION Study of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer – Karim Fizazi
September 19, 2021
Details
The Efficacy of Olaparib in the PROfound Study – Fred Saad
September 12, 2021
Details
The NCCN Guidelines on the Use of Radium-223 in Prostate Cancer - Tanya Dorff
August 12, 2021
Details
The Clinical Implications of The VISION Trial, PSMA-Targeted Radiotherapy in Metastatic Prostate Cancer - Michael Morris
August 12, 2021
Details
Assessing Concordance in DDR Gene Alterations Between Primary Prostate Cancer and Metastases or ctDNA – Bruce Montgomery
August 10, 2021
Details
COncurrent adMinistration of Bipolar Androgen Therapy and nivolumab in men with mCRPC, The COMBAT Study - Mark Markowski
July 29, 2021
Details
Ensuring Patients Have Access to Radium-223 as a Therapeutic Option: The DORA Trial - Michael Morris
June 22, 2021
Details
The State of CRPC Treatment in Spain: Expert Opinions on Enzalutamide and Abiraterone - Elena Castro & Fernando Lopez-Campos
June 18, 2021
Details
Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel - Ronald de Wit
May 5, 2021
Details
TRANSFORMER - A Study Comparing Bipolar Androgen Therapy Vs Enzalutamide in mCRPC - Emmanuel Antonarakis
April 30, 2021
Details
Should Checkpoint Inhibitors Ever Be Used Outside of a Clinical Trial in Prostate Cancer - James Gulley
March 25, 2021
Details
How Can We Leverage Our Understanding of the Tumor Microenvironment to Improve Systemic Therapy? - Kenneth Pienta
March 25, 2021
Details
Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer: COSMIC-021 - Neeraj Agarwal
January 29, 2021
Details
NCCN Guidelines Updated for Prostate Cancer M1 Systemic Therapy Based Upon The CARD Trial - Tanya Dorff
January 18, 2021
Details
The Progress and Promise of Prostate Cancer Treatments in 2020 - Charles Ryan & Alicia Morgans
January 7, 2021
Details
Improving Quality Imaging in Prostate Cancer with Gallium 68 PSMA-11 - Johannes Czernin
January 7, 2021
Details
Discussing the Efficacy and Safety from Results of the Dose Escalation Arm of AMG 160, a Bispecific T-Cell Engager (BiTE) Immune Therapy Targeting PSMA for Metastatic Castration-Resistant Prostate Cancer - Ben Tran, Oliver Sartor, and Neal Shore
November 30, 2020
Details
Preliminary Efficacy of AMG 160 in Metastatic Castration-Resistant Prostate Cancer, Interim Results From the Phase 1 Study - Tanya Dorff
November 16, 2020
Details
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Castration-Resistant Prostate Cancer - Karim Fizazi
October 26, 2020
Details
Interim Results from AMG 160 a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) - Ben Tran
October 5, 2020
Details
Treatment Considerations For Disease Progression After Combination Therapy in mCRPC - Alicia Morgans
September 29, 2020
Details
PROfound: Olaparib for Metastatic Castrate Resistant Prostate Cancer - Thomas Keane
July 2, 2020
Details
Effect of Cabazitaxel vs Abiraterone or Enzalutamide on Patient-Reported Outcomes in mCRPC: A Pre-Planned EQ-5D-5L Analysis of the CARD Study - Neal Shore
June 27, 2020
Details
Cabazitaxel Demonstrates Improved Overall Survival when Compared to an Alternative AR-targeted Agent (CARD) - Cora Sternberg
June 21, 2020
Details
The Clinical Implications of The Efficacy and Safety in Older Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone or Enzalutamide In The CARD Trial - William Oh and Stephen Freedland
June 7, 2020
Details
Rucaparib, A PARP Inhibitor For The Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Wassim Abida
June 3, 2020
Details
IMbassador250: A Study of Atezolizumab in Combination with Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Christopher Sweeney
June 2, 2020
Details
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer - Rahul Aggarwal
May 16, 2020
Details
FDA Approves First PARP Inhibitor Rucaparib for Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Charles Ryan
May 15, 2020
Details
Outcomes from The PROCEED Registry: Survival of African-American and Caucasian Men After Sipuleucel-T Immunotherapy - Oliver Sartor
May 7, 2020
Details
Optimal Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Evan Yu
May 5, 2020
Details
The ORIOLE Trial Results Discussed: Outcomes of Observation vs SABR for Oligometastatic Prostate Cancer - Phuoc T. Tran
April 7, 2020
Details
The Clinical Implications and Health-related Quality of Life Benefits: Reviewing the CARD Study Results in Men with mCRPC - Neal Shore
February 23, 2020
Details
CARD Study Demonstrates Cabazitaxel Improves Pain and Health-Related Quality of Life Analysis in Patients with mCRPC - Karim Fizazi
February 17, 2020
Details
Optimal Steroid Use with Abiraterone - Gerhardt (Gert) Attard
January 6, 2020
Details
RET Signaling in Neuroendocrine Prostate Cancer - Justin Drake
January 6, 2020
Details
Radiation Oncology Studies: Changing the Course of Disease for Men with Metastatic Prostate Cancer - Phuoc Tran
January 21, 2020
Details
Bone Health Agents in Patients with Castrate-Resistant Prostate Cancer - Bertrand Tombal
January 16, 2020
Details
Antibody-drug Conjugates for Metastatic Urothelial Carcinoma & 177Lu-PSMA-617 for Progressive mCRPC - Scott Tagawa
November 25, 2019
Details
Clinical Implications of the CARD Trial - Cora Sternberg
November 17, 2019
Details
New Therapeutic Targets for Metastatic Castration-Resistant Prostate Cancer - Aaron LeBeau
November 8, 2019
Details
The Current State of Cell-free DNA in Prostate Cancer - Alexander Wyatt
January 14, 2020
Details
Immunotherapy and Personalized Medicine in Prostate Cancer - Akash Patnaik
November 13, 2019
Details
Cabazitaxel is a New Standard of Care for Third Line Metastatic Prostate Cancer - Bertrand Tombal
October 17, 2019
Details
Immunotherapy in Metastatic Prostate Cancer - Charles Drake
February 2, 2020
Details
Personalized Medicine in Prostate Cancer - Arpit Rao
January 24, 2020
Details
Management of Castration-Resistant Prostate Cancer - Cora Sternberg
October 7, 2019
Details
Guiding First Line Treatment Decisions for mCRPC After ADT + Docetaxel or AR Pathway Inhibitor - Mary-Ellen Taplin
September 26, 2019
Details
Local Treatment of the Primary Tumor (Radiotherapy) in the Metastatic Setting - Robert Bristow
September 25, 2019
Details
Oligometastatic Prostate Cancer – Definitions and Concepts Presentation - Robert Reiter
September 18, 2019
Details
PARP Inhibition for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Presentation - Kim Chi
September 18, 2019
Details
Treatment of Oligometastatic and Oligoprogressive CRPC Presentation - Eric Small
September 18, 2019
Details
Oligorecurrent Prostate Cancer Presentation - Piet Ost
September 18, 2019
Details
De-Novo Oligometastatic Disease: Consensus and Controversy on Aims, Options, and Rationale Presentation - Michael J. Morris
September 18, 2019
Details
Immunotherapy for Metastatic Castration Resistant Prostate Cancer Presentation - Charles Drake
September 17, 2019
Details
Results and Lessons Learned from the Consensus Conference for Developing Countries - Fernando Maluf
February 2, 2020
Details
Clinical Trial Treatment Options for Rare GU Malignancies - Bradley McGregor
September 12, 2019
Details
Local Treatment of the Primary Tumor (Surgery) in the Metastatic Setting Presentation - Thomas Steuber
September 5, 2019
Details
Report and Lessons Learned From The Consensus Conference For Developing Countries Presentation - Fernando Maluf
September 4, 2019
Details
DKK1 and Prostate Cancer - David Wise
August 1, 2019
Details
A Prognostic Model for Overall Survival in Men with Metastatic Castration-resistant Prostate Cancer - Susan Halabi
August 11, 2019
Details
Prospective, Real-World Data Analysis Showed Additional Overall Survival Benefit with Sipuleucel-T in African American Patients – Oliver Sartor
August 1, 2019
Details
Radium-223 in Clinical Practice - Phillip J. Koo
August 2, 2019
Details
Management of mCRPC using Sipuleucel-T - Evan Yu
June 22, 2019
Details
Decreased Fracture Rate When Adding Bone Protecting Agents to Radium-223: PEACE III- Bertrand F. Tombal
June 11, 2019
Details
Contemporary Sequencing in the Treatment of Prostate Cancer - Neal Shore, Alicia Morgans and Charles Ryan
May 31, 2019
Details
The Changing Therapeutic Landscape of Prostate Cancer- Nicholas Vogelzang
May 12, 2019
Details
Improved Survival Outcomes of African America Men with mCRPC Treated with Sipuleucel-T - Kelvin Moses
April 23, 2019
Details
Treatment Decisions for Patients with Metastatic Castration-resistant Prostate Cancer: A Retrospective Study of Real-World Experience - Tia Higano
March 27, 2019
Details
Racial Disparities in Prostate Cancer Treatment and Outcomes - Susan Halabi
February 12, 2019
Details
Improving Natural Killer Cell Immunotherapy for Cancer - Martin Felices
February 6, 2019
Details
Overall Survival Benefit and Racial Disparities in African American Men with Metastatic Prostate Cancer - Oliver Sartor
February 5, 2019
Details
The Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade - Wassim Abida
January 31, 2019
Details
Targeting Glutamine Metabolism Pathways for the Treatment of Prostate Cancer - Richard Lee
January 30, 2019
Details
Introducing TIN 117m for Convention Electron Therapy of mCRPC - Suresh Srivastava
January 28, 2019
Details
PROPHECY Trial: Circulating Tumor Cell as a Biomarker in mCRPC - Andrew Armstrong
December 5, 2018
Details
The Process of Metastasis in Prostate Cancer - Kenneth Pienta
November 18, 2018
Details
An Update on the PARP Inhibitor Olaparib in mCRPC Patients: Review of the Phase 2 Results & A First Look at the Phase 3 Study.
October 28, 2018
Details
Combination Therapies and Quality of Life Data in Prostate Cancer - Fred Saad
October 11, 2018
Details
Prospective Study of Low-Dose Abiraterone with Food Versus Standard Dose Abiraterone in mCRPC - Russell Szmulewitz
May 8, 2018
Details
Exercise in Men with Metastatic Castrate-Resistant Prostate Cancer, the INTERVAL Study - Interview with Fred Saad
May 3, 2018
Details
UPWARD Study - Seizure Rates in Enzalutamide-Treated Men with mCRPC - Susan Slovin
January 6, 2018
Details